title: Can bleomycin toxicity in the treatment of testis cancer be batch related?
authors.forename: A J
authors.initials: AJ
authors.lastname: Birtle
authors.forename: R A
authors.initials: RA
authors.lastname: Huddart
authors.forename: A H
authors.initials: AH
authors.lastname: Horwich
authors.forename: D P
authors.initials: DP
authors.lastname: Dearnaley
authors.forename: Z
authors.initials: Z
authors.lastname: Alexander
mesh_terms: D001761:Bleomycin / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000209:etiology*; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D012016:Reference Values; D018570:Risk Assessment; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D001761:Bleomycin